title: Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome.
abstract: Eltrombopag is a nonpeptidyl thrombopoietin receptor agonist. We evaluated the ex vivo effect of eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndromes (MDSs). At a concentration of 0.1μg/mL, eltrombopag resulted in a significant increase in the number of megakaryocytic colonies in MDS patients and healthy controls compared to baseline. This dose of eltrombopag did not exert any significant change in the proliferation rate or the survival characteristics of patient CD34(+) cells that might clinically imply an unfavorable effect on patients' outcome. These encouraging preclinical data support the rationale of using eltrombopag in the clinic for alleviation of thrombocytopenia in lower risk MDS patients.
authors.affiliation: Department of Hematology, University of Crete School of Medicine, Heraklion, Greece.
authors.forename: Irene
authors.initials: I
authors.lastname: Mavroudi
authors.forename: Katerina
authors.initials: K
authors.lastname: Pyrovolaki
authors.forename: Konstantia
authors.initials: K
authors.lastname: Pavlaki
authors.forename: Androniki
authors.initials: A
authors.lastname: Kozana
authors.forename: Maria
authors.initials: M
authors.lastname: Psyllaki
authors.forename: Christina
authors.initials: C
authors.lastname: Kalpadakis
authors.forename: Charalampos
authors.initials: C
authors.lastname: Pontikoglou
authors.forename: Helen A
authors.initials: HA
authors.lastname: Papadaki
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018952:Antigens, CD34 / Q000378:metabolism; D017209:Apoptosis / Q000187:drug effects; D001565:Benzoates / Q000627:therapeutic use*; D015153:Blotting, Western; D001854:Bone Marrow Cells / Q000187:drug effects / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects*; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D008297:Male; D055016:Megakaryocyte Progenitor Cells / Q000187:drug effects* / Q000473:pathology; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000473:pathology; D011720:Pyrazoles / Q000627:therapeutic use*; D053628:Receptors, Thrombopoietin / Q000819:agonists*; D012307:Risk Factors; D034061:Thrombopoiesis / Q000187:drug effects*; D014407:Tumor Cells, Cultured
chemical_list: D018952:Antigens, CD34; D001565:Benzoates; D006834:Hydrazines; D011720:Pyrazoles; D053628:Receptors, Thrombopoietin; C520809:eltrombopag